Storia in 6 fonti

New drug a ‘promising step forward’ for hard-to-treat lung cancer

Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung cancer

Raccontata dabiopharmadive.comstatnews.comindependent.co.ukmorningstar.comscmp.comthenextweb.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

independent.co.ukStai leggendo1 g fa

New drug a ‘promising step forward’ for hard-to-treat lung cancer

Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung cancer

originale

biopharmadive.com2 g fa

Akeso, Summit drug extends survival in closely watched lung cancer trial

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."

Leggi questa versione → originale

statnews.com1 g fa

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso and Summit Therapeutics' ivonescimab reduced the risk of death by 34% in squamous non-small cell lung cancer patients versus standard treatment, in a Phase III trial published in The Lancet. For biotech and pharma-adjacent tech buyers, the result validates dual-mechanism oncology biologics and strengthens Summit's pipeline valuation ahead of potential ex-China regulatory filings.

Leggi questa versione → originale

scmp.com23 h fa

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Leggi questa versione → originale

thenextweb.com22 h fa

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's plenary in 61 years, targeting a $20B market.

Leggi questa versione → originale

morningstar.com1 g fa

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to…

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted…

Leggi questa versione → originale

Timeline cronologica

1. domenica 31 maggio 2026·biopharmadive.com
   

   Akeso, Summit drug extends survival in closely watched lung cancer trial

   Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies…

2. domenica 31 maggio 2026·statnews.com
   

   Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

   A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

3. domenica 31 maggio 2026·independent.co.uk
   

   New drug a ‘promising step forward’ for hard-to-treat lung cancer

   Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung cancer

4. domenica 31 maggio 2026·morningstar.com
   

   Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy…

   Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with…

5. domenica 31 maggio 2026·independent.co.uk
   

   Newly developed drug helps extend the lives of lung cancer patients in trial

   Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…

6. lunedì 1 giugno 2026·scmp.com
   

   Akeso lung cancer drug trial raises hopes in US$20b market

   Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

7. lunedì 1 giugno 2026·thenextweb.com
   

   Akeso lung cancer drug cuts death risk 34% in landmark trial

   Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's plenary in 61 years, targeting a $20B market.